The merger is a high-probability event given unanimous board support and insider voting agreements covering ~8.5% of Supernus and ~0.93% of Indivior shares. The primary risk to the timeline is HSR clearance, with the waiting period expiring September 21, 2026. Monitor for any regulatory pushback or competing proposals; the fixed exchange ratio means SUPN/INDV price ratio will converge toward 1.5401 as the close approaches. The special dividend creates a floor for INDV value but adds $1B in debt to the combined entity.
Price Chart
Executive Summary
Supernus Pharmaceuticals is merging with Indivior in an all-stock merger of equals. Each Supernus share will convert into 1.5401 Indivior shares, and Indivior will pay a $1 billion special dividend to its stockholders. Both boards unanimously recommend approval; the special meeting is set for October 15, 2026. The deal is expected to close in Q4 2026, creating a combined CNS-focused company with Supernus shareholders owning ~43.5% and Indivior shareholders ~56.5% on a fully diluted basis.
Key Financial Metrics
Key Facts
- Each Supernus share converts into 1.5401 Indivior shares (fixed exchange ratio).
- Indivior will pay a $1,000,000,000 aggregate special cash dividend to its stockholders.
- Supernus stockholders expected to own ~43.5% and Indivior stockholders ~56.5% of the combined company.
- Both boards unanimously recommend voting FOR the merger proposals.
- Special meetings for both companies are scheduled for October 15, 2026.
- No appraisal rights for either Supernus or Indivior stockholders.
- Indivior secured a $650 million senior secured term loan facility from Citibank to partially fund the special dividend.
- The combined company will be named Supernus, Inc., trade under ticker SUPN, and be led by Supernus CEO Jack A. Khattar.
- The merger is subject to stockholder approvals, HSR Act clearance, and other customary conditions.
- Termination fees: $101 million payable by Supernus; $174 million payable by Indivior.
Financial Impact
All-stock merger with a fixed exchange ratio of 1.5401 Indivior shares per Supernus share. Indivior will pay a $1,000,000,000 aggregate special dividend to its stockholders, partially funded by a $650 million senior secured term loan facility.
Risk Factors
- Failure to obtain stockholder approval from either company.
- Regulatory delays or conditions from HSR Act review.
- Inability to secure the $650 million debt financing for the special dividend, triggering the alternative dividend scenario.
- Fixed exchange ratio exposes Supernus stockholders to fluctuations in Indivior's stock price.
- Integration risks and potential loss of key personnel, especially Indivior management.
- Combined company's high debt load from the special dividend could constrain future operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001104659-26-107109 |
| Document: tm2625197-1_defm14a.htm | 0001104659-26-107109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $42.60 (+2.68%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | DEFA14A / 425 / 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Jul 22, 2026 10w ago | 8-K | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 22, 2026 10w ago | Press Release | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 20, 2026 10w ago | Court Ruling | $47.42 $46.20 | ▼ −2.57% | ▼ −2.15% | $42.60 (−10.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access